Ireland-headquartered, New York-listed Perrigo, a leading provider of consumer self-care products, has appointed Albert A Manzone, a member of the board, as interim president and CEO, replacing Patrick Lockwood-Taylor who has resigned following a determination by the board that certain personal conduct by Lockwood-Taylor was not consistent with the company’s code of conduct and core values. The conduct did not involve the company’s business, strategy, operations, financial reporting, or results of operations.
The board has initiated a search process to identify a permanent successor.
“The board . . . has full confidence in Manzone, who brings more than 30 years of global leadership experience and a proven track record of transforming businesses at inflection points and creating value as well as deep knowledge of our business, people, and self-care platform,” said Orlando D Ashford, Perrigo’s chair. “The company has made significant progress in advancing our strategy in recent years, stabilising and streamlining the business and implementing our new commercial operating model. We believe Manzone is the right leader to guide Perrigo through this transition and work with the broader leadership team to continue strengthening our company and deliver enhanced value for shareholders.”
Manzone has more than 30 years of leadership experience across consumer goods, consumer health, luxury and hospitality. Prior to joining Perrigo, he was deputy CEO of Monte-Carlo Société des Bains de Mer, a premier luxury hospitality group. Previously, he served as CEO of Whole Earth Brands, a global food company. Earlier in his career, he was president Europe at Oettinger Davidoff and held senior leadership roles at Novartis Consumer Health, Wrigley, PepsiCo, and McKinsey.
He has served as a member of the Perrigo board since 2022.
Perrigo is transitioning to a more consumer-centric health company, which has seen it sharpen its portfolio. In April, it completed the sale of its branded dermacosmetics business to Karo Healthcare for up to €332.6m. In November 2025, it announced a strategic review of its infant formula business. Also in 2025, it divested Richard Bittner to DCC Healthcare. In 2024, Esteve Healthcare acquired Perrigo’s HRA Pharma Rare Diseases for up to €275m
Press release: Perrigo InvestorRoom – Press Releases
